Trial Profile

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants with Advanced And/or Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BTX 9341 (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BioTheryX

Most Recent Events

29 Jul 2024 Planned number of patients changed to 82.
17 Jul 2024 Status changed from planning to recruiting, according to a BioTheryX media release.
17 Jul 2024 According to a BioTheryX media release, companyannounced that the first patient has been dosed in its Phase 1 clinical trial evaluating BTX-9341 at The START Center for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com